# In silico evaluation of algorithm-based clinical decision support systems: A scoping review

Michael Dorosan1\*#, Ya-Lin Chen6#, He Yan, Qingyuan Zhuang7,8, Sean Lam1-5

## Singapore Healthcare Management 2024

- <sup>1</sup> Health Services Research Centre, Singapore Health Services, Singapore <sup>2</sup> Health Services Research Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore <sup>3</sup> Health Services and Systems Research, Duke-NUS Medical School, Singapore <sup>4</sup> Duke-NUS Medical School, National University of Singapore, Singapore
- <sup>5</sup> Lee Kong Chian School of Business, Singapore Management University, Singapore
- <sup>6</sup> Department of Biomedical Informatics and Medical Education, University of Washington, WA, United States <sup>7</sup> Division of Supportive and Palliative Care, National Cancer Centre Singapore, Singapore
  - <sup>8</sup> Data and Computational Science Core, National Cancer Centre Singapore, Singapore \*michael.ayo.dorosan@singhealth.com.sg

"Joint first author

,ICU extuba

Peripheral artery disease (n=1)

Acute promyelocytic

Oncology (n=6)

Others (n

Provider-related

- Radiol Lung transplant (n

#### **KEY TAKEAWAYS**

- Scoping review about in silico evaluation of clinical usefulness for Artificial Intelligence-based clinica decision support systems.
- Establishing a classification scheme to give insights into what and how in silico evaluation methods can be used for different clinical decisions.

### INTRODUCTION

- Integrating Al in clinical decision-support (CDS) presents challenges and yet the real-world implementation has been limited [1].
- In silico evaluation methods which extend the model evaluation to consider clinical workflows aligns with the renewed focus of healthcare that includes care provider well-being among patients' experience improvement, better health of populations, and cost reduction [2].

#### Objectives

Our study investigates the scope by which in silico models have been used to evaluate CDS systems. Specifically, we provide the insights into: (1) in silico modeling paradigms, (2) clinical decision-support domains, (3) in silico evaluation metrics.

#### METHODOLOGY

#### **Review Framework**

The Arksey and O'Malley framework was the foundation of this scoping review, including (1) identifying the research question, (2) searching and identifying relevant studies, (3) study selection, (4) data extraction, (5) collection, summarising, and reporting of findings, and (5) consultation with stakeholders revolved around the concepts shown in Table 1 [3]. Searched databases include PubMed, Embase, CINAHL, PsycINFO, and Cochrane, Web of Science, IEEEXplore and Arxiv.

Table 1. Review Key Concepts

Concepts	Matching keywords
Clinical decision support (CDS) systems	Machine learning, deep learning, artificial intelligence, reinforcement learning, supervised machine learning, unsupervised machine learning, semi-supervised machine learning, self-supervised machine learning, expert system
Objective of the CDS models	Clinical decision support, clinical decision-making, prognosis, diagnosis, screening, triage
Evaluation objective	patient, process, provider, cost-effectiveness outcomes
Evaluation strategy	In silico, computer simulation, digital twin, simulation, pre-implementation, pre-deployment, computational simulation

## RESULTS

Search and screening process follows the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)[4] flowchart (Figure 1).

- Across the span from 2013 to 2023, a total of 21 articles were included.
  Common in silico simulation methods are shown in Figure 2.

- Clinical decision-support domains are shown in Figure 3. Considerations of in silico methods when measuring impact (A) and modeling (B) clinical workflows (Fig 4). Specific evaluation metrics used by the studies (Figu



Figure 2. Common In Silico Methods Figure 3. Clinical decision-support domains

Process-related (clinical workflow

COVID (n=1)

Lung cancer (n=2)

**B.** Simulation model parameters

.

Infectious disease (ID) (n=2)

#### A. In silico evaluation metrics

Wethod



cancer-related deaths OALY

length of stay

time to thrombolysis use

rankin scale score

Process Cost-effectiveness

days spent in ICU undetected cancer cases

Figure 5. Specific metrics for impact

deaths

Patient

ICER surgery related mean decrease in HBA1c

thrombolysis

Figure 4. Number of (A) studies per metric group; (B) and studies per parameter type

### CONCLUSION

- Proposed simulation strategies for CDS models are largely bespoke despite the prevalence of claims for generic, reusable models across clinical domains
- A detailed examination of the included articles reveal that providers were included as simulation parameters but not evaluation metrics.
- This review will facilitate the creation of a framework that evaluates the impact across the Quadruple Aims [2]



#### Figure 1. The PRISMA-ScR Flow Chart

- 1. Yin J, Ngiam KY, Teo HH. Role of Artificial Intelligence Applications in Real-Life Clinical Practice: Systematic Review. Journal of Medical Internet Research 2021 Apr 22;23(4):e25759. doi: 10.2196/25759
- 2. Sikka R, Morath JM, Leape L. The Quadruple Aim: care, health, cost and meaning in work. BMJ Qual Saf. 2015 Oct;24(10):608-10 Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evidence Synthesis. 2020 Oct;18(10):2119.
- 4. McGowan J, Straus S, Moher D, Langlois EV, O'Brien KK, Horsley T, Aldcroft A, Zarin W, Garitty CM, Hempel S, Lillie E. Reporting scoping reviews-PRISMA ScR extension. Journal of clinical epidemiology. 2020 Jul 1;123:177-9.







